Home › Idiopathic Pulmonary Fibrosis › South Carolina › Charleston
Idiopathic Pulmonary Fibrosis clinical trials in Charleston, SC
5 studies for Idiopathic Pulmonary Fibrosis are looking for participants at sites in and around Charleston (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)
RecruitingPhase 2
- Lowcountry Lung and Critical Care, PA, Charleston
- Medical University of South Carolina, Charleston
A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.
RecruitingPhase 2
- Research Site, Charleston
A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis
RecruitingPhase 2
- Medical University of South Carolina, Charleston
Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry
RecruitingObservational study
- Medical University of South Carolina, Charleston
WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)
RecruitingPhase 2
- WISPer Site in Charleston, SC, Charleston
Idiopathic Pulmonary Fibrosis trials in other cities
- Birmingham, AL9 studies
- New York City, NY8 studies
- Kansas City, KS7 studies
- Philadelphia, PA7 studies
- Los Angeles, CA7 studies
- Chicago, IL6 studies
- Aurora, CO6 studies
- Durham, NC6 studies
- Nashville, TN5 studies
- Dallas, TX5 studies
- Houston, TX5 studies
- Atlanta, GA5 studies
Other studies in Charleston
- Depression19 studies
- Stroke18 studies
- Heart Failure18 studies
- Non-Small Cell Lung Cancer16 studies
- Post-Traumatic Stress Disorder16 studies
- Cardiovascular Disease15 studies
- Prostate Cancer15 studies
- Cancer (all types)14 studies
- Head and Neck Squamous Cell Carcinoma14 studies
- Parkinson's Disease13 studies
- Interstitial Lung Diseases13 studies
- Breast Cancer12 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.